ReviewWorld journal of gastroenterology2016
Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Quince Gel Attenuates Experimental Ulcerative Colitis Through Antioxidant, Anti-Inflammatory and Mucosal Repair Mechanisms: Integrated Histopathological, Bioinformatic and Molecular Docking Analyses.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Advances in Colon-targeted Drug Delivery Systems: Innovative Strategies for Treating Colonic Disorders and Prospects for the Future.Current pharmaceutical biotechnology · 2025Review
- Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.Current pharmaceutical design · 2025Review
- Drug delivery methods based on nanotechnology for the treatment of eye diseases.Annals of medicine and surgery (2012) · 2023Review
- Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives.Pharmaceutics · 2023Review
- Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.Journal of nanobiotechnology · 2022Review
- Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease.Marine drugs · 2021Review
- Multi-Functionalized Nanomaterials and Nanoparticles for Diagnosis and Treatment of Retinoblastoma.Biosensors · 2021Review
- Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma.Biosensors · 2021Review
- Preparation of MSZ Hydrogel and Its Treatment of Colitis.Frontiers in pharmacology · 2021Article
- Optimising PLGA-PEG Nanoparticle Size and Distribution for Enhanced Drug Targeting to the Inflamed Intestinal Barrier.Pharmaceutics · 2020Article
- Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements.Pharmaceutics · 2020Review
- Silk fibroin-based nanotherapeutics: application in the treatment of colonic diseases.Nanomedicine (London, England) · 2019Review
- TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease.Molecules (Basel, Switzerland) · 2018Review
- Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges.Therapeutic advances in gastroenterology · 2017Review
- Low-frequency ultrasound may improve drug penetration in colonic mucosa.Translational cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy, and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting, sustained drug release, and decreased adverse effects. Here, we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition, the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.